DFTX

News

businesswire.comDefinium Therapeutics Announces New Employee Inducement Grantsbusinesswire.comJun 1

marketbeat.comDefinium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Programmarketbeat.comMay 22

businesswire.comDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conferencebusinesswire.comMay 21

businesswire.comDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorderbusinesswire.comMay 12

businesswire.comDefinium Therapeutics Announces New Employee Inducement Grantsbusinesswire.comMay 11

Trade DFTX

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

CEO: Robert Barrow
IPO Date: Nov 15, 2016

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsJul 30

EPS est. -0.55